Xtant Medical Holdings (XTNT) Cash & Equivalents (2010 - 2025)

Xtant Medical Holdings (XTNT) has reported Cash & Equivalents for 16 consecutive years, with $17.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 175.09% year-over-year to $17.1 million; the TTM figure through Dec 2025 stood at $17.1 million (up 175.09% YoY), while the FY2025 annual figure was $17.1 million, up 175.09% from the prior year.
• Cash & Equivalents advanced to $17.1 million in Q4 2025 per XTNT's latest filing, from $10.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $20.3 million in Q2 2021 and bottomed at $4.1 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $11.6 million across 5 years, with a median of $9.5 million in 2023.
• Annual changes were most pronounced in 2021 — Cash & Equivalents surged 679.28% — and 2023, when it tumbled 74.91%.
• Xtant Medical Holdings' Cash & Equivalents stood at $18.2 million in 2021, then increased by 11.26% to $20.3 million in 2022, then tumbled by 71.84% to $5.7 million in 2023, then increased by 8.47% to $6.2 million in 2024, then soared by 175.09% to $17.1 million in 2025.
• Business Quant data shows XTNT's Cash & Equivalents at $17.1 million in Q4 2025, $10.4 million in Q3 2025, and $6.9 million in Q2 2025.